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Orthopedic biofilm infections are difficult to treat and require a multidisciplinary approach
to diagnostics and management. Recent advances in the field include methods to
disrupt biofilm, sequencing tools, and antibiotic susceptibility tests for bacteria residing
in biofilm. The observation of interclonal differences in biofilm properties of the causative
microorganisms, together with considerations of comorbidities and polypharmacy in a
growing aging population, calls for a personalized approach to treat these infections. In
this article, we highlight aspects of precision medicine that may open new perspectives
in the diagnosis and management of orthopedic biofilm infections.
Keywords: biofilms, osteomyelitis, implant-related infection, minimal biofilm eradication concentration,
next-generation sequencing, metagenomic sequencing
INTRODUCTION
Biofilms generally form on a nonliving surface. In bone and joint infections, microorganisms
adhere either to dead bone (sequesters) or to implants. Hence, orthopedic biofilm infections include
chronic osteomyelitis and implant-associated infections. They represent a serious threat for the
patient and a substantial burden on the global health care industry. More than a million knee and
hip arthroplasties are performed every year in the United States (1). Projections for arthroplasties
in the United States show—in comparison to 2000 to 2014—an increase by 75, 129, and 284%
(hips) and by 110, 182, and 401% (knees) in 2025, 2030, and 2040, respectively (2). Periprosthetic
joint infections (PJIs) occur in 0.3–1.7% of patients after total replacement of the hip, in 0.5–2%
after total replacement of the knee, and in 2–9% after total replacement of the ankle (3). The
incidence of surgical site infection following open reduction and internal fixation of a fracture of
the extremities is 1–5% (4). In addition, the implant can be infected via the hematogenous route as
long as it remains in the body (5, 6). These arguments underscore the importance of the endeavor
to constantly advance research on bone and joint infections.
Biofilm development plays a pivotal role in implant-associated infections and allows
microorganisms to survive in an environment protected by antimicrobial agents and the host
immune system (7). Successful management of orthopedic biofilm infections eradicates the
infection while preserving a pain-free functional musculoskeletal apparatus (with or without
implant). This is best achieved by combining an appropriate surgical procedure with antimicrobial
treatment and by considering the characteristics of each individual patient.
An optimal and individualized approach considers several factors, including stability of the
implant, causative pathogen and type of infection, patient’s concomitant comorbidities, and
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surgical procedure limitations. The concept of “precision
medicine” is the new frontier of the modern health care industry
and it combines multiple fields of expertise (e.g., genetics,
genomics, big data analytics, and population health) (8). It
recognizes individual variability in genes, environment, and
lifestyle for each person. Precision medicine aims to replace the
classic “one-size-fits-all” therapeutic strategy and to achieve “the
right drug, with the right dose at the right time to the right
patient” (9). By identifying patients most likely to benefit from a
specific treatment, clinical outcomes can be improved and side
effects and costs reduced. To achieve this, precision medicine
must rely on accurate diagnostic tools to effectively maximize
benefits and reduce risks to patients.
In orthopedic biofilm infections, precisionmedicine applies to
biofilm properties of the causative microorganisms. Identifying
factors associated with so-called low or high biofilm production
can influence treatment strategies. The ability of bacteria to
adhere to nonliving surfaces and the antibiotic susceptibility
patterns of biofilm—together with host and surgical factors—
may aid decision making regarding implant removal. In this
article, we examine diagnostic advances in the identification
of causative microorganisms and antimicrobial susceptibility
testing of biofilm bacteria, putting into perspective how these
methods can help individualize the management of bone and
joint infections.
ADVANCES IN THE DIAGNOSIS OF
ORTHOPEDIC BIOFILM INFECTIONS
Culture of bone or peri-implant tissue samples is the gold
standard for identifying the organism causing the infection.
Low-frequency ultrasound (i.e., sonication) is a useful tool for
the clinical microbiologist in the diagnosis of biofilm-associated
infections. Culture of sonication fluid increases the sensitivity
and microbiological yield by disrupting the bacterial biofilm
and is less affected by prior antimicrobial treatment than are
prosthetic tissue samples (10, 11).
Molecular Diagnostic Tests
Molecular diagnostic tests directly applicable to clinical samples
have rapidly developed in recent years, improving the sensitivity
of PJI diagnosis. They can be applied to both tissue and sonication
samples. Table 1 provides an overview of different molecular
techniques evaluated for the diagnosis of PJI, and displays their
corresponding sensitivity and specificity. Reported sensitivities of
PCR assays applied to DNA extracted from sonication fluid range
from 70 to 96% (12–15). Broad-range PCR assays can identify
organisms present in the panel, but will miss atypical, rare,
and nontargeted pathogens (34). Assays targeting the universal
16S rRNA gene followed by sequencing allowed researchers to
partially overcome this limit. Although, the different regions that
can be chosen as the target and the limited resolution among
closely related species still represent a barrier. This obstacle can
be tackled by next-generation sequencing (NGS)-based assays.
The term NGS, also known as massive parallel sequencing,
refers to non-Sanger-based high throughput DNA sequencing
technologies, that allow millions of small or large (depending
on the use of short or long read-based technologies) DNA
fragments to be sequenced and deciphered simultaneously and
independently (35). NGS can be applied using either a targeted
or untargeted approach. Targeted NGS focuses on selected
portions of genome, while untargeted NGS adopts an unbiased,
hypothesis-free approach to detect any portion of genome. In
clinical microbiology, after its introduction, NGS was initially
applied to cultured isolates to obtain the complete DNA sequence
of their genome at a single time (whole genome sequencing,
WGS). More recently, the method was applied directly to clinical
samples, allowing the identification of pathogens and prediction
of antimicrobial resistance (36–42). When applied directly to
clinical samples using an untargeted approach, NGS allows the
comprehensive characterization of all nucleic acids (microbial
and human) present in the sample. This approach is called
untargeted metagenomic NGS (mNGS) (43). This technique can
significantly reduce the turnaround time to diagnosis compared
with culture methods and can detect pathogens not identified by
conventional methods (38–41).
The utility of NGS/mNGS in providing a clinically useful
diagnosis was first demonstrated in infections of the central
nervous system (38, 44). It has also been successfully applied
to orthopedic infections to determine their etiology. Street
et al. showed that mNGS on sonication fluid had 88% species-
level sensitivity (28). The meta-analysis published by Li et al.
showed that sequencing assays to diagnose PJI, including NGS-
based assays, had favorable diagnostic accuracy, with a pooled
sensitivity of 0.81 and a specificity of 0.94 (33). Thoendel
et al., using mNGS on sonicate fluid, were able to identify
new potential pathogens in 44% of culture-negative PJIs (26).
Tarabichi et al. found that NGS was able to identify an
organism in almost 90% of PJI cases compared with 61% for
culture and to detect a potential pathogen in 80% of culture-
negative PJIs. The samples included synovial fluid, deep-tissue
specimens, and swabs from medullary canals. In 88% of samples,
the results were concordant with culture results, and in 9 of
11 culture-negative PJIs, the authors detected three or more
organisms (24). Wang et al. evaluated the efficacy, safety,
accuracy, and reliability of mNGS for identifying pathogens
in culture-negative PJIs. They found that antibiotic-related
complications, duration of intravenous antibiotic treatment,
and antibiotics costs in the mNGS-based treatment group
were lower than in the empiric treatment group and yielded
a favorable outcome in less time. Outcome was defined as
control of the infection and absence of recurrence during
follow-up (45). Compared to PCR-based assays, mNGS is a
relatively young technique with plenty of potential that will
inevitably improve, as demonstrated by four recent studies
where its sensitivity to diagnose PJI was above 90% in one
of them and 95% in three of them, respectively (29–32)
(Table 1). A same-day NGS diagnostic result may significantly
increase precision and efficiency while reducing the cost of
PJI care. Long-read Nanopore technology, allowing real-time
sequencing and analysis, seems promising to achieve same-day
PJI diagnosis. Wang at al. conducted a preliminary assessment
of this technology (46). The authors were able to identify
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TABLE 1 | Overview of sensitivity and specificity of different molecular techniques applied to the diagnosis of PJI.
Molecular method Clinical sample type tested No. of samples
tested
Sensitivity Specificity References
Multiplex panel PCR Sonication fluid 37 78% na (12)
Multiplex panel PCR Sonication fluid 24 96% 100% (13)
Multiplex panel PCR Sonication fluid 144 77.1% 97.9% (14)
Multiplex panel PCR Periprosthetic tissue,
sonication fluid
64 15.6%,
68.8%
96.8%,
100%
(15)
16S rRNA - Sanger Sonication fluid 69 86% 93% (16)c
16S rRNA – NGS
(pyrosequencing)
Sonication fluid 92 90% 88% (17)c
16s rRNA - Sanger Sonication fluid 366 70% 98% (18)c
16S rRNA - Sanger Periprosthetic tissue and synovial
fluid
122 68% (82%b) 98% (96%b) (19)c
16S rRNA - Sanger Biofilma 157 80% (100%b) 94.5% (98%b) (20)c
16S rRNA - Sanger Periprosthetic tissue 67 75% 94% (21)c
16S rRNA - Sanger Periprosthetic tissue 264 73% (70%b) 95.5% (96%b) (22)c
16S rRNA – NGS Sonication fluid 101 (86%b) (98%b) (23)c
16S rRNA – NGS Synovial fluid, deep tissue
specimens and swabs
65 89% 73% (24)c
16S rRNA – NGS Synovial fluid 86 (87%b) (82%b) (25)c
mNGS Sonication fluid 408 (71%b)d (96%b) (26)c
mNGS Synovial fluid 168 (67%b)e (93%b) (27)c
mNGS Sonication fluid 97 88% 88% (28)
16S rRNA – Sanger,
mNGS
Synovial fluid 63 82%,
96%
94% (29)
mNGS Synovial fluid 25 92% 92% (30)
mNGS Periprosthetic tissue 44 95.5% 91% (31)
mNGS Synovial fluid 49 96% 95% (32)
na, not available.
a Biofilm was defined as scratched samples from the surface of implants.
b The numbers in brackets represent calculations made by other authors in the context of a systematic review and meta-analysis (33).
c The study results were included in the systematic review and meta-analysis of Li et al. (33).
d In 44% of culture-negative PJI, a microorganism was identified.
e In 16% of culture-negative PJI, a microorganism was identified.
the causative microorganisms of PJI within approximately
12 hours after sample collection. Furthermore, the detection of
corresponding antimicrobial resistance determinants was faster
compared to short-read based mNGS (46). NGS performed on
cultured microorganisms isolated from a patient experiencing
two episodes of PJI within a 9-month period was crucial to
understand that the second episode was a new infection with
the same bacterial species (47). Taken together, these studies
indicate that molecular diagnostic tests in diagnosing and
managing osteoarticular infection are helpful—and potentially
superior to conventional culture methods—when applied in the
appropriate context.
Are We Ready for Metagenomics in
Routine Diagnostics?
Multiple factors promote the implementation of NGS-based tests
in routine clinical service. These include decreasing costs of
NGS technology, cost savings from the replacement of other
diagnostic tests, amount of information provided in a single
test (prediction of virulence and drug resistance, outbreak
analysis, difficult/unculturable species detection), and availability
of portable rapid sequencing technology offering real-time data
analysis, i.e., Nanopore Technologies (48, 49).
Because of the high sensitivity of NGS, findings must be
interpreted in the clinical context, as detection of DNA is not
sufficient to conclude that an identified microorganism is the
cause of the infection. On the other hand, sensitivity is critically
affected by the background level generated by human DNA
present in the sample. Implementation of NGS-based tests in
clinical settings requires standardized protocols and validation
of each step, from DNA extraction and library preparation
to bioinformatics analysis and validation and interpretation of
sequencing results. The US Food and Drug Administration
(FDA) has published general guidelines for the validation of
infectious diseases with NGS-based diagnostic tests; mNGS tests
have been meanwhile successfully validated by several groups in
Clinical Laboratory Improvement Amendments-certified clinical
laboratories (50–55). The vast number of detectable species
makes it necessary to continuously monitor and independently
confirm uncommon or unexpected results. Currently, for PJIs,
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mNGS is recommended only when patients have an inconclusive
diagnosis despite the contribution of a multidisciplinary expert
team, or in order to further investigate culture-negative PJIs
(33, 56, 57).
DIFFERENCES IN BIOFILM PRODUCTION
Biofilm formation is influenced by strain-specific properties.
It is an interaction between environmental factors, surface
structure, bacterial growth phase, and genetic determinants.
Several methods have been published for the visualization or
quantification of biofilm, including crystal violet staining and
absorbance measurement, growth on polymethylmethacrylate
beads followed by washing and sonication, scanning electron
microscopy, and others. The physical and chemical surface
properties in these assays may not necessarily reflect those in
human infections, but they are responsible for the amount
and structure of the biofilm (58). Bacteria can adhere to
various metals (59) and biofilm formation may be different
than on nonmetal material. However, irrespective of the method
applied, several studies have demonstrated differences in biofilm
production of the same species within a sample collection (60,
61). Post et al. demonstrated that, in a collection of isolates
obtained from orthopedic implant-related infections, PJI isolates
were more frequently strong biofilm formers than were isolates
from fracture fixation-device infections (60).
The differences in biofilm production between various clones
within the same species are important for personalized medicine;
the transfer of these findings into clinical practice, however, is
more challenging. The relation of biofilm production in vitro to
infection manifestations in humans has not yet been established.
For individual patients, it is important to know whether their
infection is caused by a low or a high biofilm producer. Of
note, these terms are schematic expressions without precise
definition. Additional questions include whether or not there
is an antimicrobial agent that is active against the causative
microorganism, as well as which antibiotic concentrations are
needed, and for how long, to cure the infection (62). Notably,
the site of infection is in an extravascular compartment.
Current strategies to tackle these questions include molecular
tests for biofilm properties (section Genes Involved in Biofilm
Formation and section Antimicrobial Susceptibility Testing of
Biofilm Bacteria).
Genes Involved in Biofilm Formation
The accessory gene regulator (agr) system in Staphylococcus
aureus controls the expression of MSCRAMMs (microbial
surface components recognizing adhesive matrix molecules) and
regulates the quorum-sensing system along with the P2 and P3
promoters (63). Agr is required for S. aureus emigration from
implant-associated biofilm (64). Post et al. observed statistically
significant differences between orthopedic implant-related and
non-implant-related infection isolates for the sdrE, can, clfA, and
bbp genes (60). Thus, it is conceivable that molecular analysis
may be helpful in categorizing bacterial clones into low and high
biofilm producers.
Beyond the genes associated with biofilm production, bacterial
toxins may interact with biofilm production, staphylococcal
toxins and their impact on bone and joint infections, and
factors associated with the aggregation of S. aureus in
synovial fluid. Biofilm and exotoxin interactions have been
recently reviewed elsewhere (65) and are beyond the scope of
this article.
In group B streptococcus, the two-component system CovR/S
regulates the expression of surface adhesion proteins (e.g.,
BsaB/FbsC), and CovR/S mutants show increased adherence
to host cells and biofilm formation (66–68). Patras et al. (69)
identified the biofilm regulatory protein A (BrpA) in group B
streptococci. The carbon catabolite protein A (CcpA) is involved
in the regulation of biofilm formation in oral streptococci
(70). In addition, pili—long filamentous structures growing
from the bacterial surface—have been associated with biofilm
formation (71, 72). Genes encoding for pilus components
and their development (i.e., backbone and accessory proteins,
sortase enzymes) are clustered in genomic pathogenicity
islands named PI-1,−2a, and−2b (73). Among these, PI-
2a has been associated with the strongest biofilm-forming
capacity (72).
While quantitative proteomics of strong and weak biofilm
formers reveal important regulators of biofilm formers
[e.g., Enterococcus faecalis in (74)], there is yet not a direct
association of genetic elements and clinical failure. Numerous
factors in the host-pathogen interaction and treatment
concepts of biofilm-related infections contribute to clinical
failure (75).
The constantly growing list of research findings illustrates
the high potential for detecting biofilm properties via NGS in
routine diagnostics. Thanks to technological advances, the entire
pathogen’s genome can be characterized in near real time with
a sequence coverage sufficient to detect minor genetic variants,
critical for directing clinical care decisions (48, 76, 77). This also
allows clinical scientists to obtain a pathogen’s detailed profile
in terms of clone type and presence of genetic determinants
associated with biofilm production.
Antimicrobial Susceptibility Testing of
Biofilm Bacteria
The minimal inhibitory concentrations (MICs) of antibiotics
are routinely determined by using planktonic bacteria and
do not match the concentrations that are effective in
preventing, inhibiting, reducing, or eradicating biofilm
bacteria (78). Different biofilm susceptibility endpoint
parameters have been proposed to guide the treatment of
biofilm-associated infections. These include minimal biofilm
eradicating concentration (MBEC), minimal biofilm inhibitory
concentration (MBIC), biofilm bactericidal concentration, and
biofilm prevention concentration.
The MBEC of an antibiotic agent is the concentration of
antibiotic needed to kill all viable bacteria within an established
biofilm, including persister cells. MBEC determination is not
offered in clinical microbiology diagnostic laboratories, it is
not standardized or validated to be performed routinely, and
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antibiotic exposure time is not reported. Methods for MBEC
determination have technical difficulties, leading to considerable
variability in results (79, 80). Furthermore, biofilm age is an
important factor; thus, MBEC depends on the point of readout
(e.g., 24 vs. 120 hours) (81). Host factors such as plasma and
heme increase tolerance to antibiotics. The same aged biofilm
in normal media vs. media with human plasma has been shown
to have up to a 100-fold difference in tolerance (82). This again
illustrates the importance of considering differences between
in vivo and in vitro when interpreting MBEC results. For Gram-
positive organisms,MBECs of beta-lactams and glycopeptides are
typically several 100 to 1000 times higher than the corresponding
MIC of planktonic bacteria (62). The MBEC:MIC ratio for
aminoglycosides and rifampin is typically lower than are those
for beta-lactams. However, Staphylococcus spp., Streptococcus
spp., and Enterococcus spp. may display high-level gentamicin
resistance (62, 83).
For MBECs to provide a clinically useful result, a standardized
assay is needed, in particular when considering antibiotic therapy
as part of personalized medicine (84). Consequently, interest
in antimicrobial susceptibility testing in biofilms is ongoing,
and several methods have been implemented in the last few
years (78).
Many published results derive from the MBEC device
(formerly called the Calgary device, Innovotech Inc., Edmonton,
Alberta, Canada) (85). The method is challenging, as it requires
a specific protocol for every species and a antimicrobial agent
[supplementary material in (85)]. Recently, a promising steam-
based method has been developed by Tasse et al. (86), showing
similar results to those of the MBEC device. This easy-to-handle
and easy-to-implement method points toward interinstitutional
comparability of MBEC results. However, there is a lack of data
and direct link between MBEC results and clinical outcome,
and hence, there is no scientific reasoning to favor one of
the methods.
The challenge reoccurs when transferring MBEC results to
antibiotic dosing in patients and treatment concept. It may
seem logical that high MBEC results are associated with high
biofilm production, failure to achieve the required antibiotic
concentration at the site of infection, and hence, clinical
failure. Conversely, low MBEC results may be associated with
low biofilm production, success in achieving the required
antibiotic concentration at the site of infection, and considerable
chance of clinical cure. Unfortunately, there is no such simple
linearity because many technical, material, and environmental
factors influence the microbiological result, as outlined earlier.
Nonetheless, a similar concept was recently applied on a case
basis in a context other than orthopedic infections, namely, in
a patient with a cardiac device-related infection and conduit
valve prosthesis endocarditis caused by nutritionally variant
streptococci (87). Biofilm production was investigated on three
different materials (bone cement, glass, plastic), and several
different culture media. Biofilm eradication concentrations were
examined with two different methods. All tests uniformly
demonstrated that the causative microorganism did not produce
biofilm. The MBEC results were similar to MIC results.
Conservative treatment without device removal proved to be
successful. Although the example is only a single case, it raises
(at least) three thoughts. Firstly, these concepts require fruitful
collaboration of many disciplines in a joint team effort. Secondly,
the number of required investigations for a single case is still
too high for immediate transfer to routine clinical practice. And
thirdly, depending on the complexity and specific circumstances
of a clinical case requiring treatment decision making, the
hypothesized linearity of low MBEC results and low biofilm
production may be more tempting to believe than the presumed
association of high MBEC results and high biofilm production.
PERSPECTIVE: PRECISION MEDICINE TO
AID DECISION MAKING IN ORTHOPEDIC
BIOFILM INFECTIONS
The concept of considering clone-level (rather than only species-
level) bacterial properties in themedical decision-making process
represents a promising perspective. The more invasive the
surgical procedure for removing a device, the higher the
complication rate. If we are able to identify microorganisms
with poor biofilm production by using reliable methods prior
to the planned surgical intervention, patients could potentially
benefit from conservative treatment. Conversely, unsuccessful
attempts at implant retention could be avoided in the presence
of microorganisms with strong biofilm production. Lack of
clonal analysis beyond species identification for predicting
outcome in established treatment concepts reflects a knowledge
gap, and findings supporting this approach will affect further
research beyond the field of septic surgery. Implementation
of such a concept will have cost-saving effects, considering
the duration of hospitalization expenditures associated with
avoidable surgical infections and the complications associated
with these interventions.
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